0001209191-18-056332.txt : 20181026 0001209191-18-056332.hdr.sgml : 20181026 20181026184358 ACCESSION NUMBER: 0001209191-18-056332 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181024 FILED AS OF DATE: 20181026 DATE AS OF CHANGE: 20181026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mahatme Sandesh CENTRAL INDEX KEY: 0001511034 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 181142561 MAIL ADDRESS: STREET 1: C/O CELGENE CORPORATION STREET 2: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-24 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001511034 Mahatme Sandesh 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 0 1 0 0 EVP, CFO & CBO Common Stock 2018-10-24 4 M 0 9596 23.85 A 48381 D Common Stock 2018-10-24 4 M 0 39006 13.90 A 87387 D Common Stock 2018-10-24 4 M 0 29080 13.71 A 116467 D Common Stock 2018-10-24 4 M 0 11718 13.71 A 128185 D Common Stock 2018-10-24 4 S 0 107524 127.74 D 20661 D Common Stock 2018-10-24 5 G 0 E 12012 0.00 D 8649 D Common Stock 2018-10-24 5 G 0 E 12012 0.00 A 12012 I By wife Stock Option (right to buy) 23.85 2018-10-24 4 M 0 9596 0.00 D 2022-11-05 Common Stock 9596 116009 D Stock Option (right to buy) 13.90 2018-10-24 4 M 0 39006 0.00 D 2025-02-27 Common Stock 39006 17860 D Stock Option (right to buy) 13.71 2018-10-24 4 M 0 29080 0.00 D 2026-02-28 Common Stock 29080 7899 D Stock Option (right to buy) 13.71 2018-10-24 4 M 0 11718 0.00 D 2026-02-28 Common Stock 11718 12873 D These trades were made pursuant to a Rule 10b5-1 trading plan. The shares were sold in multiple transactions at prices ranging from $120.87 to $134.39, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein. This transaction involved a gift of securities by the reporting person to his wife. The option to purchase shares is fully vested. The option vests based on time criteria (25% of the total option on 2/27/2016 and 1/48th of the total option in equal monthly installments thereafter). Half of the total options granted began vesting when the FDA provided marketing approval for eteplirsen on 9/19/2016 and the other half of the total options granted began vesting when Sarepta Therapeutics, Inc. filed a Marketing Authorization Application with the European Medicines Agency on 11/30/2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vested immediately upon achievement of the performance condition (25% of the total performance-based options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total performance-based options granted) vest over four years. 25% of the remaining options vested on the first year anniversary of the grant date, or 2/28/2017 and 1/48th of the remaining options vests monthly thereafter. The option vests based on time criteria (25% of the total option on 2/29/2017 and 1/48th of the total option in equal monthly installments thereafter). /s/ David Tyronne Howton, as attorney-in-fact for Sandesh Mahatme 2018-10-26